Skip to main content
IDCases logoLink to IDCases
. 2022 May 21;29:e01506. doi: 10.1016/j.idcr.2022.e01506

Apyretic pulmonary oedema revealing Cardiobacterium hominis endocarditis: Case report and review of literature

Laurine Milliere a,⁎,1, Caroline Loïez a, Pierre Patoz b, Audrey Charlet a, Claire Duployez a, Frédéric Wallet a
PMCID: PMC9166381  PMID: 35669524

Abstract

Cardiobacterium hominis is a member of the HACEK group of bacteria, responsible for infective endocarditis, mainly in patients with damaged or prosthetic valves. The low virulence of this organism can explain the insidious presentation and subacute or chronic progression of C. hominis infective endocarditis. Here, a 41-year-old man with a past history of surgery for a Waldhausen type aortic coarctation was hospitalised with dyspnea and chest pains revealing an acute pulmonary oedema, without fever. Transesophageal echocardiography indicated a 20 mm vegetation on biscuspid aortic valve. Six sets of blood culture were positive with Cardiobacterium hominis. In case of lack of fever, the diagnosis of infectious endocarditis is difficult because other symptoms are non-specific and biological markers of inflammatory syndrome are quiet or non-existent. This is the first case of C. hominis infectious endocarditis with a clinical presentation of acute pulmonary oedema in the literature. We report here an apyretic pulmonary oedema revealing C. hominis endocarditis and a review of the literature on apyretic infective endocarditis due to C. hominis.

Keywords: Endocarditis, Cardiobacterium hominis, Apyrexia, MALDI TOF MS, 16S RNA PCR, HACEK


The HACEK group of bacteria, Haemophilus-Aggregatibacter-Cardiobacterium-Eikenella-Kingella, are small Gram-negative rods involved in 1.3–1.4% of endocarditis [1], [2]. These microorganisms colonize the oropharynx, are slow growing, and their growth is enhanced by the presence of CO2. First identified as a Pasteurella-like organism, Slotnick and Dougherty described Cardiobacterium hominis in 1964 and gave it its present name [3]. Subsequently, C. hominis was reclassified with Suttonella indologenes in the family Cardiobacteriaceae on the basis of 16 S rRNA analysis [4]. The low virulence of this organism may explain the insidious presentation and subacute or chronic progression of C. hominis infective endocarditis, with a tendency to infect damaged or prosthetic valves [5]. Occasionally, complications may arise such as haemodynamic disturbances. We report here an apyretic pulmonary oedema revealing C. hominis endocarditis and a review of the literature on apyretic C. hominis infective endocarditis.

Case report

A 41-year-old man, with a Waldhausen type aortic coarctation operated in childhood was admitted to our hospital in a context of dyspnea and chest pains revealing an acute pulmonary oedema typical of cardiac decompensation, confirmed by X chest ray. The initial examination showed tachycardia (113/min) with blood pressure asymmetry: 130/60 mmHg in left arm and 180/80 in right arm suggesting an aortic dissection. His body temperature was 37.1 °C, respiratory rate 44 breaths/min and oxygen saturation 96%. He had a stage III dyspnea (NYHA). There were no palpable spleen and no peripheral cutaneous endocarditis symptoms. The angio CT scan performed did not reveal aortic dissection. Considering of his cardiac past, the patient was transferred in the cardiac surgery ward. Transesophageal echocardiography demonstrated a 20 mm vegetation on bicuspid aortic valve, with severe aortic insufficiency. Blood test reveal C-reactive protein level at 35 mg/L (normal range < 5 mg/L). The white blood cell count was 9.1 × 109/L with 81% of polynuclear neutrophil, the hemoglobin concentration was 11.1 g/dL, and the platelet count was 284 × 109/L. Six peripheral blood culture sets were performed and incubated in BacT/Alert Virtuo (bioMérieux, Marcy l′Etoile, France). All blood cultures became positive after 34 h of incubation and confirmed the infective endocarditis diagnosis. Gram stain showed pleiomorphic Gram-negative rods with swollen ends arranged in rosette clusters suggesting Cardiobacterium hominis. The first antimicrobial therapy initiating with oxacillin and amoxicillin was modified by ceftriaxone (4 g/day). After 72 h of incubation at 37 °C in 5–10% CO2 in a humid atmosphere, subcultures on chocolate agar plate yielded pale yellow to white colonies, measuring 1 mm (oxidase positive, catalase negative and indole positive). Identification was performed using MALDI-TOF-mass spectrometry (Brucker Daltonics, Wissembourg) giving a 1.96 score for Cardiobacterium hominis.

Antibiotic susceptibility testing was performed using disk diffusion method (BioMérieux, Marcy l′Etoile, France) on Mueller-Hinton agar supplemented with 5% horse blood and 20 mg/L ß-NAD (MHF). The strain was susceptible to amoxicillin, amoxicillin-clavulanic acid, piperacillin, cefotaxime, carbapenems, aminoglycosides and fluoroquinolones. The nitrocefin-based test (Nitrocefin SR112, Oxoid microbiology Products, USA) for beta-lactamase production was negative. The treatment with ceftriaxone (4 g/day) was therefore switched to amoxicillin (8 g/day) for 4 weeks. The evolution of infectious process was favorable and the patient remained apyretic throughout his stay. The aortic insufficiency was treated using a mechanical prosthesis after 4 days of medical antibiotic treatment. The culture of the native valve remained sterile and molecular typing with 16 S rRNA gene sequencing confirming Cardiobacterium hominis identification (accession number LR134365.1) based on a 100% identity, using the NCBI database.

Discussion

Cardiobacterium hominis is a Gram-negative facultative anaerobic, non-motile rod. It can be arranged in pairs, short chains, teardrop firms, rosettes, or clusters. C. hominis tend to retain gentian violet at apical points after Gram staining. It is a commensal species of the human oral cavity and nasopharynx but has also been described in the genital tract of some people. The low virulence of C. hominis explains the opportunistic role of this bacterium recognized as a cause of subacute or chronic infective endocarditis [5]. In 2018, a study including 17 patients with HACEK infective endocarditis was reported. The most frequent clinical characteristic was fever at admission, in 16 patients (94%) [2]. In 2019, in a review of the literature, 73 cases of infective endocarditis caused by C. hominis were described and the mainly clinical feature of these patients was also fever in 54/70 (77%) [6]. In our case, the patient presented an acute pulmonary oedema without fever on admission. Fifteen other cases of C. hominis apyretic endocarditis have been reported in the literature over the last 50 years (Table 1).

Table 1.

Review of the literature about Cardiobacterium hominis apyretic infectious endocarditis.

References Age (y) / Sex Medical history Symptoms at admission Cardiac symptoms at admission Initial laboratory investigations Outcome
[7] 58/M Attacks of chest pain Malaise and shortness of breath following an influenza-like illness Signs of aortic incompetence
Congestive heart failure
L: 6,5 × 109/L
ESR: 25 mm/h
Aortic valve replacement
Good outcome
[8] 28/M Murmurs of aortic stenosis and aortic regurgitation Fatigue
Leg pain of 2 month’s duration
Systolic and diastolic murmur
TTE: Aortic vegetations
L: 10,3 × 109/L Aortic valve replacement
Good outcome
[9] 28/M None 2 years history of transient vertiginous attacks
Intermittent vertical diplopia
Tendency to weave towards the left side while walking
Slurring of his speech
Systolic murmur
Carotid arteriography: an embolus of cerebral artery
Blood count normal Good outcome
[5] 63/F Rheumatic fever and a heart murmur
Dyspnea following exertion and atrial fibrillation
Aortic and mitral stenosis, mitral regurgitation
Right hemiparesis: a cerebral hemorrhagic infarction
Progressive symptoms of congestive heart failure Systolic murmur
Echocardiogram: mitral stenosis, right ventricular dilation, abnormal septal motion, a dilated left atrium, and abnormal aortic valve closure. No vegetations
At surgery, aortic vegetations
L: 9,1 × 109/L
ESR: 96 mm/h
Aortic and mitral valve replacement and tricuspid valve annuloplasty
Good outcome
[10] 55/M Congestive heart failure secondary to bicuspid aortic valve
Carpentier-Edwards prosthesis aortic valve replacement
Weakness
Emesis and melena
After Upper Gastrointestinal Endoscopy
Systolic murmur
Echocardiogram: Dilated, hypokinetic left ventricle with hypertrophy
At surgery, prosthetic aortic valve had vegetations
L: 29,9 × 109/L Aortic valve replacement
Good outcome
[11] 40/M Embolic occlusion of the right popliteal artery Sudden pain left calf (= embolic occlusion of the left fibular artery) Diastolic murmur
TOE: Bicuspid aortic vegetations
ESR: 6 mm/h
CRP: 37 mg/L
Aortic valve replacement
Good outcome
[12] 17/M Congenital aortic stenosis
Homograft aortic valve replacement
Dental treatment
Lethargy
Night sweats for 3 weeks
Diastolic and systolic murmur
Echocardiogram: left ventricular hypertrophy
TTE: Non-coronary cusp of the aortic homograft vegetation
Blood count normal
ESR: 4 mm/h
CRP undetectable
Aortic valve replacement
Good outcome
[13] 66/F Diabetes mellitus
Dental caries
Chest discomfort
Fatigability
Systolic and diastolic murmur
TOE: Aortic vegetations
L: 8,5 × 109/L Aortic valve replacement
Good outcome
[14] 63/M Porcine aortic valve for severe stenosis across his native bicuspid aortic valve
Dental caries and tooth erosions
Nightly sweats
Weight loss
Immune thrombocytopenic purpura refractory to steroids
Splenomegaly
Holosystolic murmur
TTE: A degenerated aortic valve prosthesis with moderate aortic stenosis and aortic insufficiency
No vegetation
L: 9.3 × 109/L Good outcome
[15] 61/M Carpentier-Edwards prosthesis aortic valve replacement
3 episodes of Streptococcus sanguinis endocarditis
Lethargy
Weight loss
Chills
Night sweats for 2 months
TTE: Minimal calcifications and an aortic insufficiency
TOE: No signs of endocarditis
L: 8,2 × 109/L
CRP: 17 mg/L
Good outcome
[16] 60/M Dermotological lesion treated with corticoids Atypical chest
Constrictive pain
Diastolic murmur
TOE: Large valvular vegetation right coronary aortic cusp
L: 9.1 × 109/L
CRP: 24 mg/L
Valve replacement
[17] 12/M Tetralogy of Fallot
Replacements of right ventricle to pulmonary artery complicated by Staphylococcus aureus mediastinitis
Poor dentition
Fatigue
Decreased endurance of 2–3 weeks duration
Systolic and diastolic murmur
Echocardiogram: Valve with a suggestion of mass attached to the leaflet
TTE: Mass on a pulmonary valve leaflet concerning for a possible vegetation
L: 5.9 × 109/L
ESR: 25 mm/h
CRP: 11.5 mg/L
Not stated
[18] 47/M Dyspnea, orthopnea, exertional chest heaviness and hemoptysis 4 months previously
Dental procedure
Worsening malaise
Fatigue
Drenching night sweats
Anorexia
Weight loss
Aortic and diastolic murmur
TOE: Bicuspid aortic vegetations
Magnetic resonance angiography: Septic cerebral embolus
L: 14.1 × 109/L
CRP: 64 mg/L
ESR: 28 mm/h
Aortic valve replacement
Residual left-sided numbness at three-month follow-up
[19] 56/M Weaned smoking
Overweight
Pelvic girdle and scapular pain
Anemia
TTE: Tricuspid valve endocarditis
TOE: Tricuspid valve vegetation
Chest scan: Septic pulmonary embolism
CRP: 69 mg/L Tricuspid valve replacement
Good outcome
[20] 60/M Valve-sparing aortic root replacement for aortic regurgitation
Dental procedure
Esophagogastroduodenoscopy and colonoscopy 4 weeks before
Fatigue with anemia over a 3-month period Holosystolic murmur
TTE and TOE: Aortic valve vegetation
Brain magnetic resonance imaging (MRI): multiple acute lacunar infarctions (= cerebral embolism)
L: 8,3 × 109/L
CRP: 5.2 mg/L
Aortic valve replacement
Good outcome

L: leukocytes, ESR: erythrocyte sedimentation rate, TTE: transthoracic echocardiography, TOE: transesophageal echocardiography, CRP: C-reactive protein

The majority of patients was male 13/15 (87%) with a median age of 56 years. Native-valve endocarditis was more common than prosthetic-valve endocarditis. Aortic valve was the site of infection the most frequently found in 12/15 (80%), the remaining sites being 1 case of tricuspid valve infection, 1 case of pulmonary valve infection and 1 case unknown. As for clinical characteristics at admission, fatigue and malaise were the most frequent in 9/15 (60%), followed by night sweats in 4/15 (27%) and weight loss in 3/15 (20%). Other symptoms found were leg pain, splenomegaly, chest pain and shortness of breath. In terms of laboratory data, in the majority of cases white blood cell count was normal in 11/15 (73%). The C-reactive protein concentration and the erythrocyte sedimentation rate were increased in 6/15 and 4/15 respectively, however the level remains low. The clinical presentation of C. hominis endocarditis is known to be insidious, particularly in the absence of fever: indeed, other symptoms are non-specific and biological markers of inflammatory syndrome are discrete or non-existent.

We note here that no case associating acute pulmonary oedema and C. hominis have been reported in the literature. This presentation was probably due to the evolution of the cardiac process complicated by C. hominis endocarditis.

In our case, six blood cultures were positive for C. hominis with a relatively short delay of 34 h. As described previously, improvements to conventional blood culture techniques allow the detection of C. hominis with available automated blood culture systems within the standard incubation period of 5–6 days in 95% of the cases if the patient did not received antibiotics [21], [22]. For all studies presented in Table 1, the microbiological diagnosis of Cardiobacterium endocarditis was made by detection of the pathogen in blood cultures, except for one case [11] diagnosed in the embolic material by broad range polymerase chain reaction amplification of 16 S ribosomal RNA.

The standard treatment of endocarditis caused by HACEK microorganisms is intravenous ceftriaxone (2 g/day) for 4 weeks in native valve and 6 weeks in prosthetic valve [23], [24]. Due to the emergence of β-lactamase producing strains [25], the detection of production of β-lactamase is required. In absence of the enzyme, the strain is susceptible to ampicillin and the treatment may be de-escalated to a more restrictive-spectrum antibiotic. Endly, ciprofloxacin may be an option for penicillin and cephalosporin intolerance [23], [24].

In the review of the 15 cases, the most common complications were embolic events in 6/15 (40%), including 3 patients with embolic lesions to the central nervous system (CNS) (50%) and 3 patients with peripheral emboli (2 patients with embolic occlusion of the fibular artery and 1 patient with pulmonary embolism). These results are in line with Wormser et al.: embolic events were seen in 44% of patients [5]. Nevertheless, CNS emboli were observed in 21–22% of cases of complications of C. hominis endocarditis [6], [26]. In most cases, the prognosis of patients is favourable [6], however valve replacement is required in the majority of cases. In our review, 11/15 patients (73%) underwent surgery therapy in addition to medical treatment.

In conclusion, this case illustrates the importance of suspecting C. hominis infectious endocarditis in patient with a clinical presentation of acute pulmonary oedema. Endocarditis should be suspected even in absence of fever.

Conflicts of interest

The authors declare that they have no conflict of interest.

References

  • 1.Chambers S.T., Murdoch D., Morris A., Holland D., Pappas P., Almela M., et al. HACEK infective endocarditis: characteristics and outcomes from a large, multi-national cohort. PloS one. 2013;8(5) doi: 10.1371/journal.pone.0063181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Ambrosioni J., Martinez-Garcia C., Llopis J., Garcia-de-la-Maria C., Hernández-Meneses M., Tellez A., et al. HACEK infective endocarditis: Epidemiology, clinical features, and outcome: a case-control study. Int J Infect Dis. 2018;76:120–125. doi: 10.1016/j.ijid.2018.08.013. [DOI] [PubMed] [Google Scholar]
  • 3.Slotnick I.J., Dougherty M. Further characterization of an unclassified group of bacteria causing endocarditis in man: Cardiobacterium hominis gen. et sp. n. Antonie van leeuwenhoek. 1964;30:261–272. doi: 10.1007/bf02046732. [DOI] [PubMed] [Google Scholar]
  • 4.Dewhirst F.E., Paster B.J., La Fontaine S., Rood J.I. Transfer of Kingella indologenes (Snell and Lapage 1976) to the genus Suttonella gen. nov. as Suttonella indologenes comb. nov.; transfer of Bacteroides nodosus (Beveridge 1941) to the genus Dichelobacter gen. nov. as Dichelobacter nodosus comb. nov.; and assignment of the genera Cardiobacterium, Dichelobacter, and Suttonella to Cardiobacteriaceae fam. nov. in the gamma division of Proteobacteria on the basis of 16S rRNA sequence comparisons. Int J Syst Bacteriol. 1990;40(4):426–433. doi: 10.1099/00207713-40-4-426. [DOI] [PubMed] [Google Scholar]
  • 5.Wormser G.P., Bottone E.J. Cardiobacterium hominis: review of microbiologic and clinical features. Rev Infect Dis. 1983;5(4):680–691. doi: 10.1093/clinids/5.4.680. [DOI] [PubMed] [Google Scholar]
  • 6.Asai N., Sakanashi D., Suematsu H., Nishiyama N., Watanabe H., Kato H., et al. Infective endocarditis caused by Cardiobacterium hominis endocarditis: A case report and review of the literature. J Infect Chemother. 2019;25(8):626–629. doi: 10.1016/j.jiac.2019.02.002. [DOI] [PubMed] [Google Scholar]
  • 7.Midgley J., LaPage S.P., Jenkins B.A., Barrow G.I., Roberts M.E., Buck A.G. Cardiobacterium hominis endocarditis. J Med Microbiol. 1970;3(1):91–98. doi: 10.1099/00222615-3-1-91. [DOI] [PubMed] [Google Scholar]
  • 8.Ellner J.J., Rosenthal M.S., Lerner P.I., McHenry M.C. Infective endocarditis caused by slow-growing, fastidious, Gram-negative bacteria. Medicine. 1979;58(2):145–158. doi: 10.1097/00005792-197903000-00003. [DOI] [PubMed] [Google Scholar]
  • 9.Wong M.J., Chan R.M. Atypical presentation of Cardiobacterium hominis endocarditis. Can Med Assoc J. 1982;127(6):511–512. [PMC free article] [PubMed] [Google Scholar]
  • 10.Pritchard T.M., Foust R.T., Cantely J.R., Leman R.B. Prosthetic valve endocarditis due to Cardiobacterium hominis occurring after upper gastrointestinal endoscopy. Am J Med. 1991;90(4):516–518. [PubMed] [Google Scholar]
  • 11.Mueller N.J., Kaplan V., Zbinden R., Altwegg M. Diagnosis of Cardiobacterium hominis endocarditis by broad-range PCR from arterio-embolic tissue. Infection. 1999;27(4–5):278–279. doi: 10.1007/s150100050030. [DOI] [PubMed] [Google Scholar]
  • 12.Currie P.F., Codispoti M., Mankad P.S., Godman M.J. Late aortic homograft valve endocarditis caused by Cardiobacterium hominis: a case report and review of the literature. Heart. 2000;83(5):579–581. doi: 10.1136/heart.83.5.579. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Lu P.L., Hsueh P.R., Hung C.C., Teng L.J., Jang T.N., Luh K.T. Infective endocarditis complicated with progressive heart failure due to beta-lactamase-producing Cardiobacterium hominis. J Clin Microbiol. 2000;38(5):2015–2017. doi: 10.1128/JCM.38.5.2015-2017.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Arnold D.M., Smaill F., Warkentin T.E., Christjanson L., Walker I. Cardiobacterium hominis endocarditis associated with very severe thrombocytopenia and platelet autoantibodies. Am J Hematol. 2004;76(4):373–377. doi: 10.1002/ajh.20127. [DOI] [PubMed] [Google Scholar]
  • 15.Braun D., Horovitz A., Bertea M., Jenni R., Günthard H.F. Aortic homograft endocarditis caused by Cardiobacterium hominis and complicated by agranulocytosis due to ceftriaxone. BMJ Case Rep. 2010 doi: 10.1136/bcr.04.2010.2894. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Wallet F., Loïez C., Decoene C., Courcol R. Rapid identification of Cardiobacterium hominis by MALDI-TOF mass spectrometry during infective endocarditis. Jpn J Infect Dis. 2011;64(4):327–329. [PubMed] [Google Scholar]
  • 17.Suresh P., Blackwood R.A. A pediatric case of Cardiobacterium hominis endocarditis. Infect Dis Rep. 2013;5(1) doi: 10.4081/idr.2013.e7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Wong D., Carson J., Johnson A. Subacute bacterial endocarditis caused by Cardiobacterium hominis: a case report. Can J Infect Dis Med Microbiol. 2015;26(1):41–43. doi: 10.1155/2015/568750. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Molet L., Revest M., Fournet M., Donal E., Bonnaure-Mallet M., Minet J., et al. A case of tricuspid valve endocarditis due to Cardiobacterium hominis which emphasizes the shift between the poverty of clinical symptoms and the severity of cardiac damages. Endocardite tricuspide à Cardiobacterium hominis illustrant le paradoxe de la pauvreté des signes cliniques malgré une atteinte valvulaire sévère. Ann Biol Clin. 2016;74(6):693–696. doi: 10.1684/abc.2016.1187. [DOI] [PubMed] [Google Scholar]
  • 20.Shingu M., Ishimaru N., Ohnishi J., Mizuki S., Kanzawa Y., Kawano K., et al. Hemolytic anemia in a patient with subacute bacterial endocarditis by Cardiobacterium hominis. Intern Med. 2021;60(21):3489–3495. doi: 10.2169/internalmedicine.6186-20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Baron E.J., Scott J.D., Tompkins L.S. Prolonged incubation and extensive subculturing do not increase recovery of clinically significant microorganisms from standard automated blood cultures. Clin Infect Dis. 2005;41(11):1677–1680. doi: 10.1086/497595. [DOI] [PubMed] [Google Scholar]
  • 22.Weinstein M.P. Emerging data indicating that extended incubation of blood cultures has little clinical value. Clin Infect Dis. 2005;41(11):1681–1682. doi: 10.1086/497603. [DOI] [PubMed] [Google Scholar]
  • 23.Baddour L.M., Wilson W.R., Bayer A.S., Fowler V.G., Jr, Tleyjeh I.M., Rybak M.J., et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. 2018;31;138(5):e78-e79. Circulation. 2015;132(15):1435–1486. doi: 10.1161/CIR.0000000000000296. [DOI] [PubMed] [Google Scholar]
  • 24.Habib G., Lancellotti P., Antunes M.J., Bongiorni M.G., Casalta J.P., Del Zotti F., et al. ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM) Eur Heart J. 2015. 2015;36(44):3075–3128. doi: 10.1093/eurheartj/ehv319. [DOI] [PubMed] [Google Scholar]
  • 25.Le Quellec A., Bessis D., Perez C., Ciurana A.J. Endocarditis due to beta-lactamase-producing Cardiobacterium hominis. Clin Infect Dis. 1994;19(5):994–995. doi: 10.1093/clinids/19.5.994. [DOI] [PubMed] [Google Scholar]
  • 26.Malani A.N., Aronoff D.M., Bradley S.F., Kauffman C.A. Cardiobacterium hominis endocarditis: Two cases and a review of the literature. Eur J Clin Microbiol Infect Dis. 2006;25(9):587–595. doi: 10.1007/s10096-006-0189-9. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from IDCases are provided here courtesy of Elsevier

RESOURCES